The jurors saw a mistrial declared this afternoon, in the first Fosamax® trial.
The famous Juror No. 5 note — along side Peter Loftus’ reporting, at the WSJ:
. . . .A judge declared a mistrial Friday in a closely watched case involving Merck & Co.’s (MRK) osteoporosis drug Fosamax after a jury failed to reach a verdict amid tense jury deliberations.
The mistrial came two days after U.S. District Judge John F. Keenan in Manhattan called for a daylong “cooling off” period as one juror claimed in a note to have been the subject of physical threats and that a chair was thrown in the jury room.
The judge declared a mistrial Friday after the jury’s forewoman indicated the jury remained deadlocked and a lawyer for Shirley Boles, a 71-year-old Florida woman who sued Merck, again asked for a mistrial. Merck opposed the mistrial motion.
“We regret very much the jury did not continue their deliberations,” Strain said. The jury appeared to be “seven-to-one in Merck’s favor,” he said.
“We will be prepared to defend this case again if a retrial is scheduled,” said Bruce N. Kuhlik, executive vice president and general counsel of Merck. “We continue to believe that the company provided appropriate and timely information about Fosamax to consumers and to the medical, scientific and regulatory communities.”
Timothy O’Brien, a lawyer for Boles, said he expects the Boles case would likely be retried in the spring. A conference has been scheduled for October.
“For Mrs. Boles, we’re going to refine her message, focus a little more on the evidence we have, so we don’t have a three- or four-week trial,” O’Brien said.
The five-woman, three-man jury began deliberations last week, but first sent out notes on Tuesday indicating they were at an impasse and couldn’t come to a consensus on whether Fosamax caused a severe jaw condition, known as osteonecrosis, suffered by Boles. . . .
This one will likely be retried in the Spring of 2010.